SCHEMBL1621377

SCHEMBL1621377

O=S(=O)(Nc1cccc(Cl)n1)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.66
ALDH1A1 P00352 3/20 0.66
HPGD P15428 2/20 0.66
HSD17B10 Q99714 2/20 0.66
GAA P10253 1/20 0.61
SLC40A1 Q9NP59 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
POLB P06746 1/20 0.55
HSD11B1 P28845 4/20 0.55
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
IL1RN P18510 1/20 0.48
KEAP1 Q14145 1/20 0.48
ERAP1 Q9NZ08 1/20 0.48
RECQL P46063 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29967512 1.00 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL6302286 0.82 LMNA (0.55) L3MBTL1POLBHSD11B1LMNANPSR1
SCHEMBL25352139 0.80 GAA (0.58) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL925179 0.80 GAA (0.58) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL19617819 0.79 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL29967633 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10SLC40A1
SCHEMBL6026817 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDHSD17B10SLC40A1
SCHEMBL29668894 0.79 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL27660476 0.79 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL29023892 0.79 KDM4E (0.65) KDM4EALDH1A1HPGDHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115124459-A Method for selectively nitrating N- (2-pyridyl) benzene sulfonamide compound 宁波大学 2022-09-30 CN disclosed
EP-2183232-B1 PI3 KINASE MODULATORS AND METHODS OF USE AMGEN INC (US) 2013-03-06 EP disclosed
US-7928140-B2 Benzothiazole PI3 kinase modulators for cancer treatment AMGEN INC. (US) 2011-04-19 US disclosed
US-7928140-B2 Benzothiazole PI3 kinase modulators for cancer treatment AMGEN INC. (US) 2011-04-19 US disclosed
US-7928140-B2 Benzothiazole PI3 kinase modulators for cancer treatment AMGEN INC. (US) 2011-04-19 US disclosed
EP-2183232-A2 PI3 KINASE MODULATORS AND METHODS OF USE Amgen, Inc (US) 2010-05-12 EP disclosed
US-20090054405-A1 PI3 kinase modulators and methods of use AMGEN INC. (US) 2009-02-26 US disclosed
US-20090054405-A1 PI3 kinase modulators and methods of use AMGEN INC. (US) 2009-02-26 US disclosed
US-20090054405-A1 PI3 kinase modulators and methods of use AMGEN INC. (US) 2009-02-26 US disclosed
WO-2009017822-A2 PI3 KINASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054405-A1 PI3 kinase modulators and methods of use PIK3CA, PIK3C2A, PIK3C2B KDM4E 2222/4885ALDH1A1 2294/4885HPGD 1884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.